Department of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Big Data Research Center, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Eur J Radiol. 2023 Aug;165:110895. doi: 10.1016/j.ejrad.2023.110895. Epub 2023 May 30.
To develop a predictive model integrating clinical and MRI features for postoperative survival in patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT).
Between January 2008 and May 2021, consecutive HCC patients with PVTT who underwent preoperative contrast-enhanced MRI and surgical resection at a tertiary hospital were retrospectively enrolled. The MR images were independently reviewed by two blinded radiologists. Univariate and multivariate Cox regression analyses were performed to construct a prognostic score for overall survival (OS).
Ninety-four patients were included (mean age, 50.1 years; 84 men). During a median follow-up period of 15.3 months, 72 (76.6%) patients died (median OS, 15.4 months; median disease-free survival [DFS], 4.6 months). The sum size of the two largest tumors (hazard ratio [HR], 3.050; p < 0.001) and tumor growth subtype (HR, 1.928; p = 0.006) on MRI, serum albumin (HR, 0.948; p = 0.02), and age (HR, 0.978; p = 0.04) were associated with OS and incorporated in the prognostic score. Accordingly, patients were stratified into a high-risk or low-risk group, and the OS in the high-risk group was shorter than that in the low-risk group for the entire cohort (11.7 vs. 25.0 months, p < 0.001) and for patients with Cheng's type I (12.1 vs. 25.9 months, p = 0.002) and type II PVTT (11.7 vs. 25.0 months, p = 0.004). The DFS in the high-risk group was shorter than that in the low-risk group for the entire cohort (4.5 vs. 6.1 months, p = 0.001).
Based on the sum size of the two largest tumors, tumor growth subtype, albumin, and age, the prognostic score allowed accurate preoperative risk stratification in HCC patients with PVTT, independent of Cheng's PVTT classification.
开发一种整合临床和 MRI 特征的预测模型,用于预测肝细胞癌(HCC)合并门静脉癌栓(PVTT)患者的术后生存情况。
本研究回顾性纳入 2008 年 1 月至 2021 年 5 月在一家三级医院接受术前增强 MRI 检查和手术切除的连续 HCC 合并 PVTT 患者。两名盲法放射科医生独立对 MR 图像进行了评估。使用单变量和多变量 Cox 回归分析构建总生存(OS)的预后评分。
共纳入 94 例患者(平均年龄为 50.1 岁;84 例男性)。中位随访 15.3 个月期间,72 例(76.6%)患者死亡(中位 OS 为 15.4 个月;中位无疾病生存[DFS]为 4.6 个月)。MRI 上两个最大肿瘤的总和大小(危险比[HR],3.050;p<0.001)和肿瘤生长亚型(HR,1.928;p=0.006)、血清白蛋白(HR,0.948;p=0.02)和年龄(HR,0.978;p=0.04)与 OS 相关,并纳入预后评分。因此,根据该评分,患者被分为高危或低危组,高危组的 OS 明显短于低危组,无论是整个队列(11.7 比 25.0 个月,p<0.001)还是 Cheng 分型 I(12.1 比 25.9 个月,p=0.002)和 II 型 PVTT(11.7 比 25.0 个月,p=0.004)。高危组的 DFS 也短于低危组,无论是整个队列(4.5 比 6.1 个月,p=0.001)。
该基于两个最大肿瘤的总和大小、肿瘤生长亚型、白蛋白和年龄的预后评分,可在不依赖 Cheng 分型的情况下,对 HCC 合并 PVTT 患者进行术前准确的风险分层。